For investors in Hong Kong

Global Life Sciences Fund

By understanding the science and business of health care, the strategy invests in companies addressing unmet medical needs or improving health care efficiencies

ISIN
IE00BF2GM042

NAV
AUD 24.25
As of 2022/01/14

1-Day Change
AUD -9.35 (-27.83%)
As of 2022/01/14

Morningstar Rating

Key investment risks:

  • The Fund's investments in equities are subject to equity market risk due to fluctuation of securities values.
  • Investments in the Fund involve general investment, currency, hedging, economic, political, policy, foreign exchange, liquidity, tax, legal, regulatory, securities financing transactions related and small/ mid-capitalisation companies related

More

  • risks. In extreme market conditions, you may lose your entire investment.
  • The Fund may invest in financial derivatives instruments for investment and efficient portfolio management purposes. This may involve counterparty, liquidity, leverage, volatility, valuation, over-the-counter transaction, credit, currency, index, settlement default and interest risks; and the Fund may suffer total or substantial losses.
  • The Fund's investments are concentrated in companies (may include small/ mid capitalization companies) with life sciences orientation and may be more volatile.
  • Investors should not only base on this document alone to make investment decisions and should read the offering documents including the risk factors for further details.

Less

Overview

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Less

ABOUT THIS FUND

  • Looks to invest in companies addressing unmet medical needs or making the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (pharmaceuticals, biotechnology, health care services, and medical devices)
  • An experienced team of specialists that seeks to understand the science and the business of health care

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Global Life Sciences | Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Performance

Discrete Performance (%)
As of 2021/12/31
A2 HAUD
 
Quarter End
As of 2021/12/31
Dec-2020 - Dec-2021 Dec-2019 - Dec-2020 Dec-2018 - Dec-2019 Dec-2017 - Dec-2018 Dec-2016 - Dec-2017
A2 HAUD 3.92 20.45 25.18 0.85 20.32
Cumulative Performance (%)
As of 2021/12/31
A2 HAUD
 
  Cumulative
  1MO 3MO 6MO YTD 1YR 3YR 5YR Since Inception
2013/10/04
A2 HAUD 6.38 2.68 1.21 3.92 3.92 56.69 90.13 160.10
CALENDAR YEAR RETURNS (%)
A2 HAUD
2017 2018 2019 2020 2021
A2 HAUD 20.32 0.85 25.18 20.45 3.92
FEE INFORMATION
Initial Charge 5.00%
Annual Charge 1.50%
Ongoing Charge
(As of 2021/06/30)
2.37%

Portfolio

Top Holdings (As of 2021/12/31)
% OF FUND
UnitedHealth Group Inc 5.27
AstraZeneca PLC 3.93
AbbVie Inc 3.03
Thermo Fisher Scientific Inc 2.95
Abbott Laboratories 2.93
Roche Holding AG 2.93
Humana Inc 2.68
Danaher Corp 2.58
Eli Lilly & Co 2.47
Boston Scientific Corp 2.27
Total 31.04
Sector Allocation % OF FUND % OF FUND (As of 2021/12/31)
Regional Allocation % OF FUND % OF FUND (As of December 31, 2021)

Documents